#BestACR20Tweets RT @drdavidliew : Mavrilimumab (anti-GM-CSF) in GCA, phase 2 GM-CSF upstream to both Th1 & Th17 pathways; potential for dx-modifying?? PNL induction then enrol+PNL taper GCA flare (ESR/CRP+Sx/imaging): mavrilimumab RRR 62% ABSTL06 https://t.co/xxjd2lTSUe https://t.co/uuBOnbk6Ab